Serina Therapeutics Operating Cycle Over Time
| SER Stock | 2.37 0.10 4.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Serina Therapeutics Performance and Serina Therapeutics Correlation. Can Biotechnology industry sustain growth momentum? Does Serina have expansion opportunities? Factors like these will boost the valuation of Serina Therapeutics. If investors know Serina will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Serina Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth (0.43) | Earnings Share (1.87) | Revenue Per Share | Quarterly Revenue Growth 1.549 | Return On Assets |
Investors evaluate Serina Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Serina Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Serina Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Serina Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Serina Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Serina Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Cycle Analysis
Compare Serina Therapeutics and related stocks such as Genenta Science SpA, Skye Bioscience Common, and Jupiter Neurosciences Operating Cycle Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNTA | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.7 K | 5.5 K | 8.8 K | 8.8 K | 8.8 K | 7.9 K | 5.3 K |
| SKYE | 268 | 268 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 27.207 | 31.29 | 29.72 |
| JUNS | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 40.9108 | 36.82 | 32.73 |
| ALGS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| BRNS | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 208 | 39.218 | 16 K | 147 | 3.6 K | 317 | 364 | 346 |
| INMB | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 8.3 K | 5.8 K | 36.7 K | 33.1 K | 34.7 K |
| XFOR | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 664 | 298 | 112 | 112 | 1.5 K | 1.5 K | 1.5 K | 1.5 K | 1.8 K | 907 |
| TELO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| GRCE | 5.7 K | 621 | 621 | 1.2 K | 1.3 K | 3.9 K | 987 | 987 | 987 | 987 | 987 | 987 | 987 | 987 | 987 | 1.1 K | 1.1 K |
| CVM | 182 | 49 K | 199.1 K | 147.8 K | 26.7 K | 21.6 K | 1.5 K | 21.7 K | 22.6 K | 16.8 K | 1.5 K | 188 | 207 | 93.7892 | 93.7892 | 84.41 | 80.19 |
Serina Therapeutics and related stocks such as Genenta Science SpA, Skye Bioscience Common, and Jupiter Neurosciences Operating Cycle description
My Equities
My Current Equities and Potential Positions
| Serina Therapeutics | SER |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 601 Genome Way, |
| Exchange | NYSE MKT Exchange |
null 2.37
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.